For US Healthcare Professionals
- Efficacy in PsO
- Safety Profile
- Mechanism of Action
- Support and Resources
- Efficacy in PsA
DISCOVER 2: MAJOR SECONDARY ENDPOINT AT WEEK 24*
IN DISCOVER 1 AT WEEK 24 (SECONDARY ENDPOINT)
57% (47/82) of patients receiving TREMFYA® q8w had an IGA score of 0 (cleared) or 1 (minimal) and ≥2 grade reduction from baseline vs 15% (12/78) of patients receiving placebo (P<0.0001).
References: 1. Data on File. Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 3. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.